## UNAUDITED FINANCIAL RESULTS
### FOR THE QUARTER ENDED 30TH JUNE, 2002

<table>
<thead>
<tr>
<th></th>
<th>30.06.2002</th>
<th>30.06.2001</th>
<th>31.03.2002 (Audited)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Net Sales &amp; Income from Operations</td>
<td>4029.5</td>
<td>2991.8</td>
<td>14005.1</td>
</tr>
<tr>
<td>2 Other Income</td>
<td>47.8</td>
<td>48.3</td>
<td>283.6</td>
</tr>
<tr>
<td>3 Total Expenditure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a) (Increase) / decrease in Stock-in-trade</td>
<td>(212.8)</td>
<td>(147.5)</td>
<td>(850.9)</td>
</tr>
<tr>
<td>b) Consumption of Materials</td>
<td>1978.8</td>
<td>1537.7</td>
<td>6907.5</td>
</tr>
<tr>
<td>c) Staff Cost</td>
<td>196.8</td>
<td>154.2</td>
<td>632.5</td>
</tr>
<tr>
<td>d) Other Expenditure</td>
<td>1244.0</td>
<td>861.7</td>
<td>4272.1</td>
</tr>
<tr>
<td>4 Interest</td>
<td>2.3</td>
<td>2.5</td>
<td>21.0</td>
</tr>
<tr>
<td>5 Depreciation</td>
<td>70.0</td>
<td>47.5</td>
<td>212.8</td>
</tr>
<tr>
<td>6 Profit (+) / Loss (-) before Tax (1+2-3-4-5)</td>
<td>798.2</td>
<td>584.0</td>
<td>3093.7</td>
</tr>
<tr>
<td>7 Provision for Taxation</td>
<td>191.9</td>
<td>140.0</td>
<td>1017.4</td>
</tr>
<tr>
<td>8 Net Profit (+) / Loss (-) (6-7)</td>
<td>606.3</td>
<td>444.0</td>
<td>2076.3</td>
</tr>
<tr>
<td>9 Paid-up Equity Share Capital</td>
<td>599.7</td>
<td>599.7</td>
<td>599.7</td>
</tr>
<tr>
<td>10 Reserves excluding Revaluation Reserves (as per balance-sheet of previous accounting year)</td>
<td></td>
<td></td>
<td>8616.8</td>
</tr>
<tr>
<td>11 Earning per Share</td>
<td>*10.11</td>
<td>*7.40</td>
<td>34.62</td>
</tr>
<tr>
<td>* Not Annualised</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Notes:
1. Provision for tax includes deferred taxation
2. The Company is exclusively in the pharmaceutical business segment
3. The Directors at their meeting held today recommended payment of dividend of Rs.7 per equity share of Rs.10/- each for the year 2001 - 2002 amounting to Rs.419.81 million.
4. The figures of the previous year have been regrouped to render them comparable with the figures of the current year.
5. The above results were taken on record at the meeting of the Board of Directors held on 24th July, 2002.
Mumbai

By order of the Board
For CIPLA LIMITED

M. K. Hamied
Joint Managing Director